ROSELLA study opens to recruitment
Ovarian cancer is the second most common gynaecologic malignancy. Most patients are asymptomatic until advanced stages of the disease, and for women with distant invasive epithelial ovarian cancer, the five-year survival is approximately 30%. Despite initial therapy, [...]















